Cardiotoxicity screening: a review of rapid-throughput in vitro approaches

Abassi YA, Xi B, Li N et al (2012) Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment. Br J Pharmacol 165(5):1424–1441 Abe AM, Hein DJ, Gregory PJ (2015) Regulatory alerts for dietary supplements in Canada and the United States, 2005–13. Am J Health Syst Pharm 72(11):966–971 Abriel H, Rougier JS, Jalife J (2015) Ion channel macromolecular complexes in cardiomyocytes: roles in sudden cardiac death. Circ Res 116(12):1971–1988 Agarwal AK, Ram J, Singh R (2014) Sparfloxacin-associated corneal epithelial toxicity. BMJ Case Rep. doi:10.1136/bcr-2014-203786 Apostolakis S, Oeff M, Tebbe U, Fabritz L, Breithardt G, Kirchhof P (2013) Flecainide acetate for the treatment of atrial and ventricular arrhythmias. Expert Opin Pharmacother 14(3):347–357 Asakura K, Hayashi S, Ojima A et al (2015) Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes. J Pharmacol Toxicol Methods 75:17–26 Baudenbacher F, Schober T, Pinto JR et al (2008) Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. J Clin Investig 118(12):3893–3903 Beacham DW, Blackmer T, O’Grady M, Hanson GT (2010) Cell-based potassium ion channel screening using the FluxOR assay. J Biomol Screen 15(4):441–446 Beattie KA, Luscombe C, Williams G et al (2013) Evaluation of an in silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge. J Pharmacol Toxicol Methods 68(1):88–96 Becker N, Stoelzle S, Gopel S et al (2013) Minimized cell usage for stem cell-derived and primary cells on an automated patch clamp system. J Pharmacol Toxicol Methods 68(1):82–87 Becquemont L, Delespierre T, Bauduceau B et al (2014) Consequences of dextropropoxyphene market withdrawal in elderly patients with chronic pain. Eur J Clin Pharmacol 70(10):1237–1242 Bellocq C, Wilders R, Schott JJ et al (2004) A common antitussive drug, clobutinol, precipitates the long QT syndrome 2. Mol Pharmacol 66(5):1093–1102 Benay S, Meille C, Kustermann S et al (2015) Model-based assessment of erlotinib effect in vitro measured by real-time cell analysis. J Pharmacokinet Pharmacodyn 42(3):275–285 Bento AP, Gaulton A, Hersey A et al (2014) The ChEMBL bioactivity database: an update. Nucleic Acids Res 42(Database issue):D1083–D1090 Bezprozvanny I, Tsien RW (1995) Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol 48(3):540–549 Binah O, Dolnikov K, Sadan O et al (2007) Functional and developmental properties of human embryonic stem cells-derived cardiomyocytes. J Electrocardiol 40(6 Suppl):S192–S196 Blayney LM, Lai FA (2009) Ryanodine receptor-mediated arrhythmias and sudden cardiac death. Pharmacol Ther 123(2):151–177 Boverhof DR, Zacharewski TR (2006) Toxicogenomics in risk assessment: applications and needs. Toxicol Sci 89(2):352–360 Braam SR, Mummery CL (2010) Human stem cell models for predictive cardiac safety pharmacology. Stem Cell Res 4(3):155–156 Brana I, Tabernero J (2010) Cardiotoxicity. Ann Oncol 21(Suppl 7):vii173–vii179 Bridal TR, Margulis M, Wang X, Donio M, Sorota S (2010) Comparison of human Ether-a-go-go related gene screening assays based on IonWorks Quattro and thallium flux. Assay Drug Dev Technol 8(6):755–765 Bridgland-Taylor MH, Hargreaves AC, Easter A et al (2006) Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. J Pharmacol Toxicol Methods 54(2):189–199 Bruggemann A, Stoelzle S, George M, Behrends JC, Fertig N (2006) Microchip technology for automated and parallel patch-clamp recording. Small 2(7):840–846 Burashnikov A, Antzelevitch C (2003) Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation 107(18):2355–2360 Butola S, Rajagopal M (2015) Ban on dextropropoxyphene is unjustifiable. Indian J Palliat Care 21(1):3–7 Cao X, Lee YT, Holmqvist M et al (2010) Cardiac ion channel safety profiling on the IonWorks Quattro automated patch clamp system. Assay Drug Dev Technol 8(6):766–780 Cao Z, Hammock BD, McCoy M, Rogawski MA, Lein PJ, Pessah IN (2012) Tetramethylenedisulfotetramine alters Ca2+ dynamics in cultured hippocampal neurons: mitigation by NMDA receptor blockade and GABA(A) receptor-positive modulation. Toxicol Sci 130(2):362–372 Cao Z, Cui Y, Busse E, Mehrotra S, Rainier JD, Murray TF (2014) Gambierol inhibition of voltage-gated potassium channels augments spontaneous Ca2+ oscillations in cerebrocortical neurons. J Pharmacol Exp Ther 350(3):615–623 Cao Z, Zou X, Cui Y et al (2015) Rapid throughput analysis demonstrates that chemicals with distinct seizurogenic mechanisms differentially alter Ca2+ dynamics in networks formed by hippocampal neurons in culture. Mol Pharmacol 87(4):595–605 Cardinale D, Bacchiani G, Beggiato M, Colombo A, Cipolla CM (2013) Strategies to prevent and treat cardiovascular risk in cancer patients. Semin Oncol 40(2):186–198 Castle N, Printzenhoff D, Zellmer S, Antonio B, Wickenden A, Silvia C (2009) Sodium channel inhibitor drug discovery using automated high throughput electrophysiology platforms. Comb Chem High Throughput Screen 12(1):107–122 Chen J, Seebohm G, Sanguinetti MC (2002) Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc Natl Acad Sci USA 99(19):12461–12466 Chen X, Yang L, Zhai SD (2012) Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies. Chin Med J 125(23):4301–4306 Cheng YP, Ma T, He RR (2003) Electrophysiological effects of phytoestrogen genistein on spontaneous activity of rabbit atrioventricular node cells. Sheng Li Xue Bao 55(1):9–13 Cheng F, Li W, Zhou Y et al (2012) admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model 52(11):3099–3105 Chevalier M, Amuzescu B, Gawali V et al (2014) Late cardiac sodium current can be assessed using automated patch-clamp. F1000Res 3, p 245 Clements M, Thomas N (2014) High-throughput multi-parameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays. Toxicol Sci 140(2):445–461 Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT (1995) A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80(5):795–803 Danker T, Moller C (2014) Early identification of hERG liability in drug discovery programs by automated patch clamp. Front Pharmacol 5:203 Dennis AT, Wang L, Wan H, Nassal D, Deschenes I, Ficker E (2012) Molecular determinants of pentamidine-induced hERG trafficking inhibition. Mol Pharmacol 81(2):198–209 Ding M, Stjernborg L, Albertson N (2006) Application of cryopreserved cells to HERG screening using a non-radioactive Rb+ efflux assay. Assay Drug Dev Technol 4(1):83–88 Doddareddy MR, Klaasse EC, Shagufta Ijzerman AP, Bender A (2010) Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases. ChemMedChem 5(5):716–729 Doherty KR, Talbert DR, Trusk PB, Moran DM, Shell SA, Bacus S (2015) Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types. Toxicol Appl Pharmacol 285(1):51–60 Dorn A, Hermann F, Ebneth A et al (2005) Evaluation of a high-throughput fluorescence assay method for HERG potassium channel inhibition. J Biomol Screen 10(4):339–347 Du F, Yu H, Zou B, Babcock J, Long S, Li M (2011) hERGCentral: a large database to store, retrieve, and analyze compound-human Ether-a-go-go related gene channel interactions to facilitate cardiotoxicity assessment in drug development. Assay Drug Dev Technol 9(6):580–588 Dunlop J, Bowlby M, Peri R, Vasilyev D, Arias R (2008) High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nat Rev Drug Discov 7(4):358–368 Durdagi S, Randall T, Duff HJ, Chamberlin A, Noskov SY (2014) Rehabilitating drug-induced long-QT promoters: in silico design of hERG-neutral cisapride analogues with retained pharmacological activity. BMC Pharmacol Toxicol 15:14 Echt DS, Liebson PR, Mitchell LB et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324(12):781–788 Elkins RC, Davies MR, Brough SJ et al (2013) Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment. J Pharmacol Toxicol Methods 68(1):112–122 Farre C, Fertig N (2012) HTS techniques for patch clamp-based ion channel screening—advances and economy. Expert Opin Drug Discov 7(6):515–524 Farre C, Fertig N (2014) New strategies in ion channel screening for drug discovery: are there ways to improve its productivity? Expert Opin Drug Discov 9(10):1103–1107 Farre C, Stoelzle S, Haarmann C, George M, Bruggemann A, Fertig N (2007) Automated ion channel screening: patch clamping made easy. Expert Opin Ther Targets 11(4):557–565 Farre C, Haythornthwaite A, Haarmann C et al (2009) Port-a-patch and patchliner: high fidelity electrophysiology for secondary screening and safety pharmacology. Comb Chem High Throughput Screen 12(1):24–37 Fendyur A, Spira ME (2012) Toward on-chip, in-cell recordings from cultured cardiomyocytes by arrays of gold mushroom-shaped microelectrodes. Front Neuroeng 5:21 Fenton M, Rathbone J, Reilly J, Sultana A (2007) Thioridazine for schizophrenia. Cochrane Database Syst Rev 18(3):CD001944 Fernandez D, Ghanta A, Kauffman GW, Sanguinetti MC (2004) Physicochemical features of the HERG channel drug binding site. J Biol Chem 279(11):10120–10127 Ficker E, Jarolimek W, Kiehn J, Baumann A, Brown AM (1998) Molecular determinants of dofetilide block of HERG K+ channels. Circ Res 82(3):386–395 Filz O, Lagunin A, Filimonov D, Poroikov V (2008) Computer-aided prediction of QT-prolongation. SAR QSAR Environ Res 19(1–2):81–90 Fornaro P, Calabria G, Corallo G, Picotti GB (2002) Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotics: a dopamine hypothesis. Doc Ophthalmol 105(1):41–49 Frea S, Giustetto C, Capriolo M et al (2015) New echocardiographic insights in short QT syndrome: More than a channellopathy? Heart Rhythm 12(10):2096–2105 Genschow E, Spielmann H, Scholz G et al (2002) The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. European Centre for the Validation of Alternative Methods. ATLA 30(2):151–176 Gfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V (2014) SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Res 42(Web Server issue):W32–W38 Giacomini E, Buonfiglio R, Masetti M et al (2015) A ligand-based virtual screening approach to identify small molecules as HERG channel activators. Comb Chem High Throughput Screen 18(3):269–280 Giudicessi JR, Ackerman MJ (2013) Arrhythmia risk in long QT syndrome: beyond the disease-causative mutation. Circul Cardiovasc Genet 6(4):313–316 Guo L, Abrams RM, Babiarz JE et al (2011) Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci 123(1):281–289 Guthrie H, Livingston FS, Gubler U, Garippa R (2005) A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system. J Biomol Screen 10(8):832–840 Halbach M, Egert U, Hescheler J, Banach K (2003) Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures. Cell Physiol Biochem 13(5):271–284 Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ (1981) Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391(2):85–100 Hamilton KL, Harris AC, Gewirtz JC (2013) Affective and neuroendocrine effects of withdrawal from chronic, long-acting opiate administration. Brain Res 1538:73–82 Harding SE, Ali NN, Brito-Martins M, Gorelik J (2007) The human embryonic stem cell-derived cardiomyocyte as a pharmacological model. Pharmacol Ther 113(2):341–353 Harris K, Aylott M, Cui Y, Louttit JB, McMahon NC, Sridhar A (2013) Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicol Sci 134(2):412–426 Hassan HA, El-Gharib NE (2015) Obesity and clinical riskiness relationship: therapeutic management by dietary antioxidant supplementation—a review. Appl Biochem Biotechnol 176(3):647–69 Hayes JF, Bhaskaran K, Batterham R, Smeeth L, Douglas I (2015) The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom. Int J Obes (Lond) 39(9):1359–1364 Haythornthwaite A, Stoelzle S, Hasler A et al (2012) Characterizing human ion channels in induced pluripotent stem cell-derived neurons. J Biomol Screen 17(9):1264–1272 Himmel HM (2013) Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds. J Pharmacol Toxicol Methods 68(1):97–111 Hondeghem LM, Dujardin K, Hoffmann P, Dumotier B, De Clerck F (2011) Drug-induced QTC prolongation dangerously underestimates proarrhythmic potential: lessons from terfenadine. J Cardiovasc Pharmacol 57(5):589–597 Huang XP, Mangano T, Hufeisen S, Setola V, Roth BL (2010) Identification of human Ether-a-go-go related gene modulators by three screening platforms in an academic drug-discovery setting. Assay Drug Dev Technol 8(6):727–742 Huang W, Lu C, Wu Y, Ouyang S, Chen Y (2015) T-type calcium channel antagonists, mibefradil and NNC-55-0396 inhibit cell proliferation and induce cell apoptosis in leukemia cell lines. J Exp Clin Cancer Res 34(1):54 Huikuri HV, Castellanos A, Myerburg RJ (2001) Sudden death due to cardiac arrhythmias. N Engl J Med 345(20):1473–1482 Huikuri HV, Raatikainen MJ, Moerch-Joergensen R et al (2009) Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction. Eur Heart J 30(6):689–698 Ishii K, Kondo K, Takahashi M, Kimura M, Endoh M (2001) An amino acid residue whose change by mutation affects drug binding to the HERG channel. FEBS Lett 506(3):191–195 Jorgensen S, Dyhring T, Brown DT, Strobaek D, Christophersen P, Demnitz J (2013) A high-throughput screening campaign for detection of Ca(2+)-activated K(+) channel activators and inhibitors using a fluorometric imaging plate reader-based Tl(+)-influx assay. Assay Drug Dev Technol 11(3):163–172 Kamiya K, Mitcheson JS, Yasui K, Kodama I, Sanguinetti MC (2001) Open channel block of HERG K(+) channels by vesnarinone. Mol Pharmacol 60(2):244–253 Karamatskos E, Lambert M, Mulert C, Naber D (2012) Drug safety and efficacy evaluation of sertindole for schizophrenia. Expert Opin Drug Saf 11(6):1047–1062 Keating MT, Sanguinetti MC (2001) Molecular and cellular mechanisms of cardiac arrhythmias. Cell 104(4):569–580 Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK (2007) Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25(2):197–206 Keks N, McGrath J, Lambert T et al (1994) The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia. Acta Psychiatr Scand 90(5):358–365 Khorassani FE, Misher A, Garris S (2015) Past and present of antiobesity agents: focus on monoamine modulators. Am J Health Syst Pharm 72(9):697–706 Kim Kjaerulff S, Wich L, Kringelum J et al (2013) ChemProt-20: visual navigation in a disease chemical biology database. Nucleic Acids Res 41(Database issue):D464–D469 Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3(8):711–715 Kujala K, Paavola J, Lahti A et al (2012) Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations. PLoS One 7(9):e44660 Kurtzwald-Josefson E, Hochhauser E, Bogachenko K et al (2014) Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice. Heart Rhythm 11(8):1471–1479 Lacerda AE, Kuryshev YA, Chen Y et al (2008) Alfuzosin delays cardiac repolarization by a novel mechanism. J Pharmacol Exp Ther 324(2):427–433 Lahti AL, Kujala VJ, Chapman H et al (2012) Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Models Mech 5(2):220–230 Lees-Miller JP, Duan Y, Teng GQ, Duff HJ (2000) Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol Pharmacol 57(2):367–374 Li Q, Rottlander M, Xu M et al (2011) Identification of novel KCNQ4 openers by a high-throughput fluorescence-based thallium flux assay. Anal Biochem 418(1):66–72 Liu QN, Trudeau MC (2015) Eag domains regulate LQT mutant hERG channels in human induced pluripotent stem cell-derived cardiomyocytes. PLoS One 10(4):e0123951 Liu X, Vogt I, Haque T, Campillos M (2013) HitPick: a web server for hit identification and target prediction of chemical screenings. Bioinformatics 29(15):1910–1912 London B, Michalec M, Mehdi H et al (2007) Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation 116(20):2260–2268 Lu HR, Vlaminckx E, Hermans AN et al (2008) Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B guidelines. Br J Pharmacol 154(7):1427–1438 Ly JQ, Shyy G, Misner DL (2007) Assessing hERG channel inhibition using PatchXpress. Clin Lab Med 27(1):201–208 Ma J, Guo L, Fiene SJ et al (2011) High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol 301(5):H2006–H2017 MacDonald JS, Robertson RT (2009) Toxicity testing in the 21st century: a view from the pharmaceutical industry. Toxicol Sci 110(1):40–46 Maeno Y, Hirose A, Kanbe T, Hori D (2009) Fetal arrhythmia: prenatal diagnosis and perinatal management. J Obstet Gynaecol Res 35(4):623–629 Mandenius CF, Steel D, Noor F et al (2011) Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-the-art bioanalytics: a review. J Appl Toxicol 31(3):191–205 McNair WP, Ku L, Taylor MR et al (2004) SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation 110(15):2163–2167 Medeiros-Domingo A, Kaku T, Tester DJ et al (2007) SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome. Circulation 116(2):134–142 Meyer T, Boven KH, Gunther E, Fejtl M (2004) Micro-electrode arrays in cardiac safety pharmacology: a novel tool to study QT interval prolongation. Drug Saf 27(11):763–772 Miller D, Wang L, Zhong J (2014) Chapter twelve—sodium channels, cardiac arrhythmia, and therapeutic strategy. In: Ya-Xiong T (ed) Advances in pharmacology, vol 70. Academic Press, London p, pp 367–392 Mitcheson JS (2003) Drug binding to HERG channels: evidence for a ‘non-aromatic’ binding site for fluvoxamine. Br J Pharmacol 139(5):883–884 Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC (2000) A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 97(22):12329–12333 Moller C (2010) Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology. Expert Rev Clin Pharmacol 3(3):321–329 Moric-Janiszewska E, Herbert E, Cholewa K, Filipecki A, Trusz-Gluza M, Wilczok T (2004) Mutational screening of SCN5A linked disorders in Polish patients and their family members. J Appl Genet 45(3):383–390 Nabel EG (2003) Cardiovascular disease. N Engl J Med 349(1):60–72 Navarrete EG, Liang P, Lan F et al (2013) Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation 128(11 Suppl 1):S3–S13 Nguemo F, Saric T, Pfannkuche K, Watzele M, Reppel M, Hescheler J (2012) In vitro model for assessing arrhythmogenic properties of drugs based on high-resolution impedance measurements. Cell Physiol Biochem 29(5–6):819–832 Nickel J, Gohlke BO, Erehman J et al (2014) SuperPred: update on drug classification and target prediction. Nucleic Acids Res 42(Web Server issue):W26–W31 Niedernberg A, Tunaru S, Blaukat A, Ardati A, Kostenis E (2003) Sphingosine 1-phosphate and dioleoylphosphatidic acid are low affinity agonists for the orphan receptor GPR63. Cell Signal 15(4):435–446 Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356(24):2457–2471 Numann R, Negulescu PA (2001) High-throughput screening strategies for cardiac ion channels. Trends Cardiovasc Med 11(2):54–59 Pan T, Khare S, Ackah F et al (2013) In vitro cytotoxicity assessment based on KC(50) with real-time cell analyzer (RTCA) assay. Comput Biol Chem 47:113–120 Pan T, Li H, Khare S et al (2015) High-throughput screening assay for the environmental water samples using cellular response profiles. Ecotoxicol Environ Saf 114:134–142 Peters MF, Lamore SD, Guo L, Scott CW, Kolaja KL (2015) Human stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line. Cardiovasc Toxicol 15(2):127–139 Pfeufer A, Jalilzadeh S, Perz S et al (2005) Common variants in myocardial ion channel genes modify the QT interval in the general population: results from the KORA study. Circ Res 96(6):693–701 Pouton CW, Haynes JM (2007) Embryonic stem cells as a source of models for drug discovery. Nat Rev Drug Discov 6(8):605–616 Pradhapan P, Kuusela J, Viik J, Aalto-Setala K, Hyttinen J (2013) Cardiomyocyte MEA data analysis (CardioMDA)–a novel field potential data analysis software for pluripotent stem cell derived cardiomyocytes. PLoS One 8(9):e73637 Priest BT, Bell IM, Garcia ML (2008) Role of hERG potassium channel assays in drug development. Channels 2(2):87–93 Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL (2011) Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf 20(7):772–777 Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F (2005) QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev 25(2):133–166 Redfern WS, Carlsson L, Davis AS et al (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58(1):32–45 Roy M, Dumaine R, Brown AM (1996) HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94(4):817–823 Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N (2014) Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J 167(3):292–300 Sager PT, Seltzer J, Turner JR et al (2015) Cardiovascular Safety Outcome Trials: a meeting report from the Cardiac Safety Research Consortium. Am Heart J 169(4):486–495 Sanchez-Chapula JA, Navarro-Polanco RA, Culberson C, Chen J, Sanguinetti MC (2002) Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block. J Biol Chem 277(26):23587–23595 Sanchez-Chapula JA, Ferrer T, Navarro-Polanco RA, Sanguinetti MC (2003) Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol Pharmacol 63(5):1051–1058 Sanguinetti MC, Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440(7083):463–469 Scheel O, Frech S, Amuzescu B, Eisfeld J, Lin KH, Knott T (2014) Action potential characterization of human induced pluripotent stem cell-derived cardiomyocytes using automated patch-clamp technology. Assay Drug Dev Technol 12(8):457–469 Schmitt N, Grunnet M, Olesen SP (2014) Cardiac potassium channel subtypes: new roles in repolarization and arrhythmia. Physiol Rev 94(2):609–653 Scott CW, Zhang X, Abi-Gerges N, Lamore SD, Abassi YA, Peters MF (2014) An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility. Toxicol Sci 142(2):331–338 Simpson JM, Maxwell D, Rosenthal E, Gill H (2009) Fetal ventricular tachycardia secondary to long QT syndrome treated with maternal intravenous magnesium: case report and review of the literature. Ultrasound Obstet Gynecol 34(4):475–480 Sirenko O, Hesley J, Rusyn I, Cromwell EF (2014) High-content high-throughput assays for characterizing the viability and morphology of human iPSC-derived neuronal cultures. Assay Drug Dev Technol 12(9–10):536–547 Splawski I, Timothy KW, Sharpe LM et al (2004) Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119(1):19–31 Splawski I, Timothy KW, Decher N et al (2005) Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci USA 102(23):8089–8096 (discussion 8086-8) Stansfeld PJ, Gedeck P, Gosling M, Cox B, Mitcheson JS, Sutcliffe MJ (2007) Drug block of the hERG potassium channel: insight from modeling. Proteins 68(2):568–580 Steffensen AB, Refsgaard L, Andersen MN et al (2015) IKs Gain- and loss-of-function in early-onset lone atrial fibrillation. J Cardiovasc Electrophysio 26(7):715–723 Stoelzle S, Haythornthwaite A, Kettenhofen R et al (2011) Automated patch clamp on mESC-derived cardiomyocytes for cardiotoxicity prediction. J Biomol Screen 16(8):910–916 Su X, Young EW, Underkofler HA, Kamp TJ, January CT, Beebe DJ (2011) Microfluidic cell culture and its application in high-throughput drug screening: cardiotoxicity assay for hERG channels. J Biomol Screen 16(1):101–111 Tang W, Kang J, Wu X et al (2001) Development and evaluation of high throughput functional assay methods for HERG potassium channel. J Biomol Screen 6(5):325–331 Tester DJ, Kopplin LJ, Will ML, Ackerman MJ (2005) Spectrum and prevalence of cardiac ryanodine receptor (RyR2) mutations in a cohort of unrelated patients referred explicitly for long QT syndrome genetic testing. Heart Rhythm 2(10):1099–1105 Thomas SH, Higham PD, Hartigan-Go K et al (1995) Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence. Br Heart J 74(1):53–56 Villoutreix BO, Taboureau O (2015) Computational investigations of hERG channel blockers: new insights and current predictive models. Adv Drug Deliv Rev 86:72–82 Wang T, Hu N, Cao J, Wu J, Su K, Wang P (2013) A cardiomyocyte-based biosensor for antiarrhythmic drug evaluation by simultaneously monitoring cell growth and beating. Biosens Bioelectron 49:9–13 Wang Y, Suzek T, Zhang J et al (2014) PubChem BioAssay: 2014 update. Nucleic Acids Res 42(Database issue):D1075–D1082 Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT (1998) An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med 339(11):725–732 Wible BA, Hawryluk P, Ficker E, Kuryshev YA, Kirsch G, Brown AM (2005) HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods 52(1):136–145 Wilhelms M, Rombach C, Scholz EP, Dossel O, Seemann G (2012) Impact of amiodarone and cisapride on simulated human ventricular electrophysiology and electrocardiograms. Europace 14(Suppl 5):v90–v96 Witchel HJ, Hancox JC, Nutt DJ (2003a) Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 23(1):58–77 Witchel HJ, Hancox JC, Nutt DJ, Wilson S (2003b) Antipsychotics, HERG and sudden death. Br J Psychiatry 182:171–172 Xi B, Wang T, Li N et al (2011) Functional cardiotoxicity profiling and screening using the xCELLigence RTCA Cardio System. J Lab Autom 16(6):415–421 Xia M, Shahane SA, Huang R et al (2011) Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels. Toxicol Appl Pharmacol 252(3):250–258 Zaniboni M, Pollard AE, Yang L, Spitzer KW (2000) Beat-to-beat repolarization variability in ventricular myocytes and its suppression by electrical coupling. Am J Physiol Heart Circ Physiol 278(3):H677–H687 Zeng H, Penniman JR, Kinose F et al (2008) Improved throughput of PatchXpress hERG assay using intracellular potassium fluoride. Assay Drug Dev Technol 6(2):235–241 Zhang H, Zou B, Yu H et al (2012) Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel. Proc Natl Acad Sci USA 109(29):11866–11871 Zhou Z, Vorperian VR, Gong Q, Zhang S, January CT (1999) Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol 10(6):836–843